West Pharmaceutical Services, Inc. (WST) Sees Price Target Increase Following Strong Quarterly Performance

• Evercore ISI upgrades NYSE:WST to "Outperform" with a price target increase to $390.
• Q3 2025 earnings report shows an adjusted EPS of $1.96, beating expectations with a +17.37% earnings surprise.
• Annual profit forecast revised upwards, driven by strong demand for GLP-1 weight-loss and diabetes drug components.

West Pharmaceutical Services, Inc. (NYSE: WST) is a prominent player in the medical equipment industry, specializing in the production of components for healthcare products. The company is known for its Proprietary Products and Contract Manufacturing segments, which have shown strong performance. As of October 23, 2025, Evercore ISI upgraded its rating for WST to "Outperform," with a price target increase from $350 to $390. At the time, WST was trading at $309.35.

The upgrade from Evercore ISI comes on the heels of West Pharmaceutical's impressive third-quarter 2025 earnings. The company reported adjusted earnings per share (EPS) of $1.96, surpassing analyst expectations of $1.68. This represents a significant earnings surprise of +17.37%, as highlighted by Zacks. The company's net sales reached $804.6 million, a 7.7% increase from the previous year, exceeding the expected $787.93 million.

West Pharmaceutical's strong performance is driven by its Proprietary Products and Contract Manufacturing segments. Sales of Proprietary Products rose to $647.5 million, reflecting a 7.7% increase, with a 5.1% rise on an organic basis. Contract-Manufactured Products also saw growth, with sales reaching $157.1 million, up 8.0% and 4.9% on an organic basis. The company's HVP Components business experienced double-digit growth, fueled by demand for GLP-1 products and increased HVP conversion.

The company's robust financial results have led to an upward revision of its annual profit forecast. West Pharmaceutical attributes this positive outlook to the strong demand for its components, which are essential for GLP-1 weight-loss and diabetes drugs. This surge in demand has contributed to better-than-expected financial results, prompting the company to adjust its profit expectations upward.

WST's stock has seen a notable increase, currently priced at $308.33, reflecting an 11.31% rise. The stock has fluctuated between a low of $300 and a high of $322.34 during the day. Over the past year, WST has reached a high of $352.33 and a low of $187.43. The company's market capitalization stands at approximately $22.17 billion, with a trading volume of 996,599 shares on the NYSE.

• Recent performance of West Pharmaceutical Services, Inc. (NYSE:WST) indicates resilience with a 1.75% gain over the past 30 days, despite a minor dip of about 1.45% in the last 10 days.
• The company has a significant growth potential of over 10.52%, with analysts setting a target price of $278, suggesting a substantial upside.
• WST's Piotroski Score of 8 underscores its strong financial health, highlighting its robust profitability, liquidity, and operational efficiency.

West Pharmaceutical Services, Inc. (NYSE:WST) is a leading provider of innovative solutions for injectable drug administration. The company specializes in the design and manufacture of packaging components and delivery systems for injectable drugs and healthcare products. With a strong presence in the pharmaceutical and biotechnology sectors, West Pharmaceutical Services competes with companies like AptarGroup and Gerresheimer.

WST has shown a promising blend of recent performance metrics and future growth potential. Over the past 30 days, the stock has gained approximately 1.75%, indicating resilience amidst market fluctuations. This upward trend suggests that WST is maintaining a positive trajectory, even as it navigates short-term market volatility.

Despite a minor decline of about 1.45% in the last 10 days, WST's overall trajectory remains strong. This recent dip could present a buying opportunity for investors looking to capitalize on potential rebounds. The stock's ability to maintain a positive trajectory over the past month highlights its resilience and potential for future growth.

WST boasts a significant growth potential of over 10.52%, underscoring the market's confidence in the company's ability to expand and increase its market value. Analysts have set a target price of $278 for WST, suggesting a substantial upside from its current trading levels. This target price reflects the company's strong fundamentals and growth prospects.

The company's Piotroski Score of 8 indicates strong financial health, reflecting robust profitability, liquidity, and operational efficiency. This score reinforces WST's solid foundation and future prospects, making it a compelling investment choice for those seeking a blend of stability and growth potential.

• West Pharmaceutical Services, Inc. (NYSE:WST) faces a decline in analysts' expectations with a current price target of $245, down from $319.
• Recent financial disclosures reveal challenges, including destocking in its High-Value Products portfolio and operational inefficiencies, impacting stock performance.
• Investors are advised to watch for the upcoming second-quarter financial results on July 24, 2025, amidst ongoing investigations by Faruqi & Faruqi, LLP for potential federal securities law violations.

West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the healthcare industry, specializing in containment and delivery systems for injectable drugs. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. It serves a diverse clientele, including pharmaceutical, biologic, and medical device companies. Founded in 1923, West is headquartered in Exton, Pennsylvania.

The current consensus price target for West is not explicitly stated, but recent data shows a stable short-term target of $245 over the last month and quarter. This stability suggests that analysts' expectations for West have not shifted significantly in the short term. UBS, however, has set a slightly higher price target of $250, indicating some positive expectations for the company's performance.

Over the past year, the average price target for West has declined from $319 to $245. This decline reflects a decrease in analysts' expectations for the stock. Several factors could contribute to this, including changes in market conditions, company performance, and industry trends. Notably, West's recent financial disclosures revealed challenges such as destocking in its High-Value Products portfolio and operational inefficiencies in its SmartDose device.

West's recent financial disclosures have impacted its stock performance. On February 13, 2025, the company issued weak revenue and earnings forecasts for the year, attributing the disappointing guidance to contract manufacturing headwinds. This included the loss of two major continuous glucose monitoring customers, leading to a significant stock price drop of $123.17 per share, closing at $199.11.

Investors should stay informed about West's upcoming second-quarter financial results, set to be released on July 24, 2025. The company will host a conference call to discuss these results and future business expectations. Additionally, Faruqi & Faruqi, LLP is investigating potential claims against West, alleging violations of federal securities laws. Investors are reminded of the July 7, 2025 deadline to seek the role of lead plaintiff in the class action.

• West Pharmaceutical Services, Inc. (NYSE:WST) is set to release its first-quarter 2025 earnings with Wall Street anticipating an EPS of $1.22 and revenue projections of approximately $686.3 million.
• The company has a history of exceeding earnings expectations, with a track record of surpassing estimates three times in the last four quarters.
• Despite a projected year-over-year EPS decrease of 16.7%, WST's strong financial position is highlighted by a P/E ratio of 32.55 and a debt-to-equity ratio of 0.11, indicating resilience in a challenging market.

West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the pharmaceutical industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. The company is known for its strong presence in the biologics and contract manufacturing sectors. As WST prepares to release its first-quarter 2025 earnings, investors are keenly watching the anticipated figures.

Wall Street estimates WST's earnings per share (EPS) to be $1.22, with projected revenue of approximately $686.3 million. However, the Zacks Consensus Estimate suggests a slightly higher EPS of $1.30 and revenue of $686.5 million. Despite these projections, internal estimates indicate a potential revenue of $686.2 million, reflecting a 1.1% organic growth from the previous year.

The company's performance in the previous quarter exceeded earnings expectations by 4%, and over the last four quarters, WST has surpassed earnings estimates three times, with an average surprise of 8.33%. This track record of exceeding expectations could influence investor sentiment positively if the upcoming results align with or surpass estimates.

Financially, WST maintains a strong position with a price-to-earnings (P/E) ratio of 32.55 and a price-to-sales ratio of 5.49. The company's low debt-to-equity ratio of 0.11 and a current ratio of 2.79 indicate a conservative capital structure and strong liquidity. These metrics suggest that WST is well-positioned to navigate potential market fluctuations following the earnings release.

• West Pharmaceutical Services, Inc. (NYSE:WST) is set to release its first-quarter 2025 earnings with Wall Street anticipating an EPS of $1.22 and revenue projections of approximately $686.3 million.
• The company has a history of exceeding earnings expectations, with a track record of surpassing estimates three times in the last four quarters.
• Despite a projected year-over-year EPS decrease of 16.7%, WST's strong financial position is highlighted by a P/E ratio of 32.55 and a debt-to-equity ratio of 0.11, indicating resilience in a challenging market.

West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the pharmaceutical industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. The company is known for its strong presence in the biologics and contract manufacturing sectors. As WST prepares to release its first-quarter 2025 earnings, investors are keenly watching the anticipated figures.

Wall Street estimates WST's earnings per share (EPS) to be $1.22, with projected revenue of approximately $686.3 million. However, the Zacks Consensus Estimate suggests a slightly higher EPS of $1.30 and revenue of $686.5 million. Despite these projections, internal estimates indicate a potential revenue of $686.2 million, reflecting a 1.1% organic growth from the previous year.

The company's performance in the previous quarter exceeded earnings expectations by 4%, and over the last four quarters, WST has surpassed earnings estimates three times, with an average surprise of 8.33%. This track record of exceeding expectations could influence investor sentiment positively if the upcoming results align with or surpass estimates.

Financially, WST maintains a strong position with a price-to-earnings (P/E) ratio of 32.55 and a price-to-sales ratio of 5.49. The company's low debt-to-equity ratio of 0.11 and a current ratio of 2.79 indicate a conservative capital structure and strong liquidity. These metrics suggest that WST is well-positioned to navigate potential market fluctuations following the earnings release.